Stress Echo Ultrasound Contrast in an Urban Safety Net Hospital to Refine Ischemia Evaluation

NCT ID: NCT01572220

Last Updated: 2017-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study is designed to have broad generalizability and inform a potential shift toward greater utilization of stress echocardiography with UCA. This will be accomplished by comparing UCA stress echocardiography with myocardial SPECT among hospitalized patients presenting with atraumatic chest pain. This study seeks to demonstrate: clinical comparability of the 2 modalities (based on non-diagnostic test rates), improved care efficiency (based on length of stay), lower costs, improved provider satisfaction, and a presumed improved safety profile through the elimination of radiation exposure.

Primary Hypothesis: A strategy of routine UCA (Optison™) enhanced stress echocardiography will result in a clinically non-diagnostic test rate comparable to myocardial SPECT among patients hospitalized (inpatient or hospital observation status) with atraumatic chest pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chest Pain Symptomatic Ischemic Equivalent

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hospitalized patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

stress echocardiography

Comparative effectiveness

Group Type OTHER

UCA stress echocardiography or myocardial SPECT

Intervention Type OTHER

Comparative Effectiveness of cardiac stress imaging modalities

Myocardial SPECT

CER

Group Type OTHER

UCA stress echocardiography or myocardial SPECT

Intervention Type OTHER

Comparative Effectiveness of cardiac stress imaging modalities

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UCA stress echocardiography or myocardial SPECT

Comparative Effectiveness of cardiac stress imaging modalities

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females aged ≥ 18 years
2. Evaluated for symptoms of chest discomfort or ischemic equivalent
3. Clinical indication for stress imaging, defined as one of the following clinical risk estimates for CAD based upon the Diamond and Forrester classification7:

* Intermediate pretest probability of CAD and electrocardiogram (ECG) is clinically interpretable and patient is able to exercise
* Intermediate pretest probability of CAD and ECG is clinically interpretable or patient is unable to exercise
* High pretest probability of CAD regardless of ECG interpretability and ability to exercise
4. Willing and able to provide written informed consent to participate in this study
5. Agrees to remain under observation (e.g., inpatient or observational status) until all study procedures from the hospital stay are completed, and to complete a 30-day follow up call

Exclusion Criteria

1. Documented medical history or discovery during screening and/or admission of any of the following:

* Severe aortic or mitral stenosis
* Significant resting left ventricular outflow tract obstruction (velocity \> 3 cm/s)
* Mobile left ventricular apical thrombus
* Acute pericarditis or pericardial tamponade
* Ascending or thoracic aortic aneurysm that is not stable or meets surgical criteria
* Acute decompensated congestive heart failure
* Established severe left ventricular systolic dysfunction (left ventricular ejection fraction \< 35%)
2. Definite acute coronary syndrome (e.g., unstable angina, acute myocardial infarction) as confirmed by elevated Troponin I (\>0.6 ng/L) on two successive measurements or ECG changes diagnostic for unstable angina (e.g. localized ST changes) in conjunction with clinical appraisal
3. Any of the following other abnormalities on the ECG at screening:

* Paced ventricular rhythm or complete left bundle branch block
* Uncontrolled arrhythmias defined by frequent premature ventricular complexes (PVCs) \> 10/minute, non-sustained ventricular tachycardia, or atrial fibrillation with rapid ventricular response
* 2nd or 3rd degree heart block
4. Uncontrolled hypertension defined as systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 110 mmHg at screening
5. Hemoglobin (Hb) \< 7.5 mg/dL at screening or within 3 months prior to screening
6. Potassium \< 3.0 mmol/L or \> 5.5 mmol/L or severe electrolyte abnormality at screening that, in the opinion of the supervising physician or Investigator, makes stress testing unsafe
7. Females who are pregnant or nursing
8. Known intolerance to any of the study stress agents (dipyridamole, dobutamine) or study cardiac imaging agents (Optison, Cardiolite)
9. Weight ≥ 350lbs
10. Any physical or psychological condition that, in the opinion of the Investigator, may adversely affect the safety of the patient if enrolled in this trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

General Electric

INDUSTRY

Sponsor Role collaborator

Denver Health and Hospital Authority

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mori Krantz

Principal Investigator, Cardiologist, MD FACC FACP

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mori Krantz, MD FACC FACP

Role: PRINCIPAL_INVESTIGATOR

Denver Health Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Denver Health Medical Center

Denver, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med. 1999 May 4;130(9):719-28. doi: 10.7326/0003-4819-130-9-199905040-00003.

Reference Type BACKGROUND
PMID: 10357690 (View on PubMed)

Berrington de Gonzalez A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, Land C. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009 Dec 14;169(22):2071-7. doi: 10.1001/archinternmed.2009.440.

Reference Type BACKGROUND
PMID: 20008689 (View on PubMed)

Fazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH, Shah ND, Nasir K, Einstein AJ, Nallamothu BK. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009 Aug 27;361(9):849-57. doi: 10.1056/NEJMoa0901249.

Reference Type BACKGROUND
PMID: 19710483 (View on PubMed)

Kisacik HL, Ozdemir K, Altinyay E, Oguzhan A, Kural T, Kir M, Kutuk E, Goksel S. Comparison of exercise stress testing with simultaneous dobutamine stress echocardiography and technetium-99m isonitrile single-photon emission computerized tomography for diagnosis of coronary artery disease. Eur Heart J. 1996 Jan;17(1):113-9. doi: 10.1093/oxfordjournals.eurheartj.a014669.

Reference Type BACKGROUND
PMID: 8682117 (View on PubMed)

Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979 Jun 14;300(24):1350-8. doi: 10.1056/NEJM197906143002402.

Reference Type BACKGROUND
PMID: 440357 (View on PubMed)

Salame G, Juselius WE, Burden M, Long CS, Bendelow T, Beaty B, Masoudi FA, Krantz MJ. Contrast-Enhanced Stress Echocardiography and Myocardial Perfusion Imaging in Patients Hospitalized With Chest Pain: A Randomized Study. Crit Pathw Cardiol. 2018 Jun;17(2):98-104. doi: 10.1097/HPC.0000000000000141.

Reference Type DERIVED
PMID: 29768319 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.asecho.org/files/AUCEcho.pdf

6\. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12-0009

Identifier Type: -

Identifier Source: org_study_id